← Eichor
Condition: Malignant Melanoma Stage Iii Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Malignant Melanoma Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Phase 3 · 3 location(s) · Hildur Helgadottir · NCT06794775Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT06771544A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
NA · 20 location(s) · Uppsala University · NCT03116412Versatile Ampification Single-Molecule Detection in Liquid Biopsy
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT05940311MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Phase N/A · 39 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT03605771Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
NA · 1 location(s) · Erasmus Medical Center · NCT05652673Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve
NA · 1 location(s) · Mayo Clinic · NCT07379138Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Phase 2 · 1 location(s) · Di Wu · NCT04331093Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
Phase 2 · 6 location(s) · UNICANCER · NCT07230613Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in
NA · 1 location(s) · Xijing Hospital · NCT07586891Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NA · 7 location(s) · Craig L Slingluff, Jr · NCT05839912To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Phase 1 · 2 location(s) · Inge Marie Svane · NCT06204991Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
NA · 1 location(s) · Kelly McMasters · NCT04513028Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NA · 7 location(s) · Miltenyi Biomedicine GmbH · NCT06508775Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT05527795A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06594991Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Phase 3 · 26 location(s) · Uppsala University · NCT06488482Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melan
Phase 3 · 110 location(s) · Regeneron Pharmaceuticals · NCT06246916A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Bet
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302607NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Phase N/A · 1 location(s) · University of Wisconsin, Madison · NCT06199713IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04562129Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
Phase N/A · 27 location(s) · Assistance Publique - Hôpitaux de Paris · NCT02828202Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
EARLY_Phase 1 · 1 location(s) · Xijing Hospital · NCT07586904
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.